| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
BIIB
Biogen
|
Jun 17, 2026 | HOLD |
Strong Buy
+25.1% avg upside
51 analysts
|
$196.00
0.37% Downside
|
+0.0% |
|
ABCL
AbCellera Biologics
|
Jun 17, 2026 | BUY |
Strong Buy
+139.4% avg upside
15 analysts
|
$7.00
26.56% Upside
|
· |
|
INCY
Incyte
|
Jun 14, 2026 | SELL |
Buy
+1.0% avg upside
47 analysts
|
$75.00
23.70% Downside
|
+2.9% |
|
LLY
Eli Lilly & Co
|
Jun 14, 2026 | BUY |
Strong Buy
-10.5% avg upside
47 analysts
|
$1300.00
18.34% Upside
|
-2.7% |
|
NVO
Novo Nordisk
|
Jun 07, 2026 | HOLD |
Buy
+168.1% avg upside
26 analysts
|
$45.00
4.19% Upside
|
+6.1% |
|
PFE
Pfizer
|
Jun 06, 2026 | BUY |
Buy
+34.1% avg upside
45 analysts
|
$34.00
34.82% Upside
|
-1.6% |
|
GPCR
Structure Therapeutics, Inc. Sponsored ADR
|
Jun 05, 2026 | BUY |
Strong Buy
+132.5% avg upside
17 analysts
|
$145.00
225.81% Upside
|
· |
|
IRON
Disc Medicine
|
Jun 02, 2026 | BUY |
Strong Buy
+20.3% avg upside
21 analysts
|
$100.00
41.32% Upside
|
+3.1% |
|
TSHA
Taysha Gene Therapies
|
Jun 01, 2026 | BUY |
Strong Buy
+103.3% avg upside
21 analysts
|
$10.00
55.72% Upside
|
+3.7% |
|
REGN
Regeneron
|
May 21, 2026 | BUY |
Strong Buy
+26.9% avg upside
57 analysts
|
$730.00
19.62% Upside
|
-5.4% |
|
BMY
Bristol-Myers Squibb
|
May 13, 2026 | HOLD |
Buy
+9.1% avg upside
42 analysts
|
$60.00
11.18% Upside
|
-2.0% |
|
ACAD
ACADIA Pharmaceuticals
|
May 11, 2026 | BUY |
Strong Buy
+66.0% avg upside
42 analysts
|
$34.00
57.20% Upside
|
-0.9% |
|
BNTX
BioNTech SE
|
May 11, 2026 | BUY |
Strong Buy
+50.5% avg upside
26 analysts
|
$128.00
40.80% Upside
|
-2.6% |
|
NBIX
Neurocrine
|
May 11, 2026 | HOLD |
Strong Buy
+7.8% avg upside
37 analysts
|
$144.00
9.02% Downside
|
+6.1% |
|
SDGR
Schrodinger
|
May 05, 2026 | BUY |
Strong Buy
+80.6% avg upside
14 analysts
|
$24.00
52.27% Upside
|
+12.3% |
|
MRK
Merck & Company
|
May 04, 2026 | BUY |
Strong Buy
+10.7% avg upside
43 analysts
|
$135.00
18.51% Upside
|
+2.8% |
|
AMGN
Amgen
|
May 04, 2026 | BUY |
Buy
-11.6% avg upside
57 analysts
|
$400.00
18.48% Upside
|
+5.0% |
|
VRTX
Vertex Pharmaceuticals
|
May 04, 2026 | BUY |
Strong Buy
-2.7% avg upside
61 analysts
|
$600.00
32.86% Upside
|
+6.8% |
|
ABBV
AbbVie
|
May 04, 2026 | BUY |
Buy
+2.8% avg upside
43 analysts
|
$258.00
19.19% Upside
|
+6.3% |
|
REPL
Replimune Group
|
Apr 13, 2026 | SELL |
Hold
+72.3% avg upside
13 analysts
|
$1.00
90.20% Downside
|
-499.4% |
|
GILD
Gilead Sciences
|
Apr 07, 2026 | BUY |
Strong Buy
-4.8% avg upside
66 analysts
|
$174.00
40.65% Upside
|
-10.2% |
|
SRRK
Scholar Rock Holding
|
Mar 18, 2026 | BUY |
Strong Buy
+20.2% avg upside
23 analysts
|
$70.00
47.82% Upside
|
+18.0% |
|
PTGX
Protagonist Therapeutics
|
Oct 13, 2025 | BUY |
Strong Buy
-22.1% avg upside
19 analysts
|
$112.00
0.82% Downside
|
+40.8% |
|
ARVN
Arvinas Holding Company
|
Sep 30, 2025 | HOLD |
Buy
+265.4% avg upside
27 analysts
|
— | -11.0% |
|
NGNE
Neurogene
|
Sep 30, 2025 | HOLD |
Buy
+55.9% avg upside
23 analysts
|
— | +59.9% |
|
CCCC
C4 Therapeutics
|
May 06, 2025 | HOLD |
Strong Buy
+341.8% avg upside
19 analysts
|
— | +107.8% |
|
DE:MRK
Merck KGaA
|
Oct 23, 2024 | BUY |
Buy
+2.1% avg upside
32 analysts
|
$130.19
2.24% Downside
|
· |
|
CADL
Candel Therapeutics
|
Aug 07, 2023 | HOLD |
Strong Buy
+112.6% avg upside
10 analysts
|
— | +369.2% |
|
NUVB
Nuvation Bio
|
May 09, 2023 | HOLD |
Strong Buy
+132.2% avg upside
15 analysts
|
— | +106.8% |
|
IMA
ImageneBio
|
Aug 13, 2021 | BUY |
Strong Buy
+179.6% avg upside
12 analysts
|
$27.00
350.04% Upside
|
-51.6% |
|
GRTX
Galera Therapeutics
|
Dec 16, 2020 | BUY |
Buy
+6826.8% avg upside
7 analysts
|
$15.00
17402.83% Upside
|
· |
|
NL:LKFT
Galapagos
|
Oct 16, 2020 | HOLD |
Sell
+112.3% avg upside
16 analysts
|
$129.00
424.74% Upside
|
· |
|
TLPH
Talphera
|
Aug 13, 2020 | SELL |
Buy
+339.6% avg upside
15 analysts
|
$0.84
22.89% Downside
|
+5.7% |
|
MGNX
MacroGenics
|
May 11, 2020 | BUY |
Buy
+326.4% avg upside
25 analysts
|
$30.00
626.42% Upside
|
+16.1% |
|
LKFT
Lakefront Biotherapeutics
|
Feb 24, 2020 | HOLD |
Hold
+272.9% avg upside
24 analysts
|
$220.00
677.37% Upside
|
· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.